Get started
Author

Derrick van Beuge

Observed names: D. van Beuge, Derrick van Beuge³
OpenAlex ID: A5148755314
210 | Real‐world Comparative Effectiveness of First‐line Bruton Tyrosine Kinase Inhibitors in Patients With Chronic Lymphocytic Leukemia
2025 · R. Jacobs, X. Wang, et al. · Hematological Oncology · 2
PDF
Real-world comparative effectiveness of first-line Bruton tyrosine kinase inhibitors (BTKis) in patients with chronic lymphocytic leukemia (CLL).
2025 · Ryan Jacobs, Xiaoliang Wang, et al. · Journal of Clinical Oncology · 1
PDF
CLL-476: Real-World Comparative Analysis of Treatment Discontinuation With Covalent Bruton Tyrosine Kinase Inhibitors in First-Line Chronic Lymphocytic Leukemia
2026 · Nakhle Saba, Erin Mulvey, et al. · Clinical Lymphoma Myeloma & Leukemia
CLL-169: Real-World Impact of Atrial Fibrillation on Cardiovascular Outcomes and Healthcare Resource Utilization in Patients With Chronic Lymphocytic Leukemia
2026 · Michael Fradley, Daniel Addison, et al. · Clinical Lymphoma Myeloma & Leukemia
CLL-991: Treatment Burden Among Patients Aged 75 Years or Older With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
2026 · Daniel A Ermann, Aseel Alsouqi, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CLL-476: Real-World Comparative Analysis of Treatment Discontinuation With Covalent Bruton Tyrosine Kinase Inhibitors in First-Line Chronic Lymphocytic Leukemia
2026 · Nakhle Saba, Erin Mulvey, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CLL-169: Real-World Impact of Atrial Fibrillation on Cardiovascular Outcomes and Healthcare Resource Utilization in Patients With Chronic Lymphocytic Leukemia
2026 · Michael Fradley, Daniel Addison, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CLL-991: Treatment Burden Among Patients Aged 75 Years or Older With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
2026 · Daniel A Ermann, Aseel Alsouqi, et al. · Clinical Lymphoma Myeloma & Leukemia
Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL
2026 · Daniel A. Ermann, Deborah M. Stephens, et al. · Oncology and Therapy
PDF
Real-World Impact of Atrial Fibrillation on Cardiovascular Outcomes and Healthcare Resource Utilization in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
2026 · Daniel Ermann, Daniel Addison², et al. · Journal of Oncology Research and Therapy
PDF
Eph115 Validation of Algorithms to Identify Cardiac-related Deaths in Population-based Studies Using a Claims Database
2026 · Ryan Jacobs, Alessandra Ferrajoli, et al. · Value in Health
Real-world treatment utilization, sequencing patterns, and healthcare resource utilization in Waldenström macroglobulinemia (WM).
2026 · Jorge Julio Castillo, Qianhong Fu, et al. · Journal of Clinical Oncology
Incidence of cardiac-related deaths (CRDs) among patients (pts) aged ≥ 65 years with B-cell malignancies (BCMs) treated with ibrutinib (ibr).
2026 · Ryan Jacobs, Xiaoliang Wang, et al. · Journal of Clinical Oncology
Real-world impact of atrial fibrillation (AFib) on cardiovascular (CV) outcomes and healthcare resource utilization (HCRU) in patients with chronic lymphocytic leukemia (CLL).
2026 · Michael Fradley, Daniel Addison, et al. · Journal of Clinical Oncology
Real-world outcomes among Medicare beneficiaries treated with first-line (1L) Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL).
2026 · Daniel Arthur Ermann, Deborah M. Stephens, et al. · Journal of Clinical Oncology
PDF
Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia
2025 · Brian Koffman, Xiaoliang Wang, et al. · Blood
PDF
Incidence of cardiac-related deaths among patients aged ≥65 years with B-cell malignancies treated with ibrutinib
2025 · Ryan Jacobs, Alessandra Ferrajoli, et al. · Blood
PDF
Mediators of racial and ethnic inequities in access to front-line therapies for chronic lymphocytic leukemia in the United States: A real-world evidence study
2025 · Joanna Rhodes, Adam Kittai, et al. · Blood
PDF
557 | Evaluating Uptake of Targeted Agents by Race/ethnicity in Patients Receiving First‐line Treatment for Chronic Lymphocytic Leukemia
2025 · A. S. Kittai, P. J. Hampel, et al. · Hematological Oncology
PDF
Evaluating uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for chronic lymphocytic leukemia (CLL).
2025 · Adam Kittai, Paul Joseph Hampel, et al. · Journal of Clinical Oncology
PDF
Works count: 20
Citation count: 3
H-index: 1
I10-index:
Year
Topic
Type